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Poliovirus 3AB protein was the first picornavirus protein demonstrated to have 
nucleic acid chaperone activity. Current results demonstrate that chaperone activity 
requires the C-terminal 22 amino acid (3B region (also referred to as VPg), amino acid 
88-109) of the protein as mutations in this region abrogated nucleic acid binding and 
chaperone activity. Protein 3B alone had no chaperone activity as determined by 
established assays testing chaperone activity including: the ability to stimulate nucleic 
acid hybridization in a primer-template annealing assay, or helix-destabilization in a 
nucleic acid unwinding assay, or aggregation of nucleic acids. In contrast, the putative 
3AB C-terminal cytoplasmic domain (N terminal amino acid 81-109, 3B + the last 7 C-
terminal amino acids of 3A, termed 3B+7 in this report) possessed strong activity in these 
assay, albeit at much higher concentrations than 3AB. Results from several mutations in 
3B+7 are described and a model proposing that 3B+7 possesses the “intrinsic” chaperone 
activity of 3AB while the 3A N-terminal region (amino acid 1-58) and/or membrane 
anchor domain (amino acid 59-80) serve to increase the effective concentration of the 





reduced chaperone activity in vitro, K81A and F83A in 3AB were tested in tissue culture. 
Viruses with these mutations produced near wildtype and minute plaques, respectively. 
F83A gave rise to revertants with either wildtype 3AB sequences or additional nearby 
compensatory mutations. Translation and polyprotein processing were not affected by 
these mutations but RNA synthesis compared to wildtype, was slightly lower for K81A 
and significantly lower for F83A. This data suggests that mutations that decrease 
chaperone activity of 3AB may lead to decreased RNA synthesis, although the exact 
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Chapter 1: Introduction 
 
1.1 A Brief History of Poliomyelitis  
Poliomyelitis is a highly infectious viral disease that causes diarrhea, vomiting, 
fatigue, muscle stiffness and in rare cases partial or complete paralysis (80). The disease 
can strike at any age but is more common among children under the age of five. The 
earliest clinical description of poliomyelitis was provided in 1789 by British physician 
Michael Underwood. Initial outbreaks in Europe and the United States were recorded in 
the early 19
th
 century. Evidence from Egyptian mummies suggests that polio existed as 
far back as 3700 B.C.  
Karl Landsteiner and Erwin Popper identified the causative agent of 
poliomyelitis, a poliovirus, in 1908, long after the disease had established itself as 
globally endemic. The disease reached a peak in the United States in 1952, with more 
than 21,000 cases of polio paralysis (21, 47). There was an urgent need for a vaccine to 
stop the spread of this dreaded disease.  Different laboratory findings across the globe 
contributed immensely to development of an effective polio vaccine. In 1952, Jonas Salk 
successfully developed a formalin-inactivated viral vaccine that was able to trigger the 
body’s immune system without potentially causing an infection. Following this, massive 
field trials were organized across the country to test its efficacy. The March of Dimes, a 
nonprofit organization established by Franklin D. Roosevelt to fight polio, successfully 
mobilized nearly two million children to participate in these field trials (58). The success 





vaccination there was a dramatic decrease in the incidence of polio by 85-90% in the 
United States between 1955-1957 (21, 52).  
Despite this great achievement, efforts to develop more effective vaccines 
continued. In 1957, Dr. Albert Sabin began testing a live, attenuated, oral form of the 
vaccine. In addition to being more cost effective due to oral administration, this version 
of the vaccine proved to confer long lasting immunity and was thus released to the public 
in 1962 (39).  With the development of two successful vaccines, a global effort to 
eradicate polio was initiated by the World Health Organization, UNICEF, Rotary Club 
International, and the Centers for Disease Control and Prevention in 1988 (48). It was one 
of the largest and most successful public health initiatives in the history of mankind. At 
the onset of the global polio eradication initiative, polio existed in 125 countries 
worldwide with 350,000 cases of infection in 1988. Twenty-four years later, the numbers 
have dropped by greater than 90% with just four countries (India, Pakistan, Afghanistan, 
and Nigeria) being endemic (48). Recently, in February 2012, India was declared polio-
free by the World Health Organization (Morbidity and Mortality Weekly Report May 
2012, CDC). 
1.2 Classification of Poliovirus 
Poliovirus is an enterovirus that belongs to the family Picornaviridae. There are 
nine genera within the family (Table 1-1), which consists of many viruses that adversely 
affect humans, agriculture and livestock. Poliovirus, Hepatitis A virus and Rhinovirus are 
important human pathogens while the Foot and Mouth Disease virus was the first 
discovered animal virus and remains one of the most important animal pathogens (97). 





as prototype model system for plus-strand RNA viruses. The study of poliovirus has 
contributed extensively not only to the field of virology but biology in general. Some 
notable examples are the discovery of mammalian uncapped messenger RNA (72), the 
internal ribosome entry sire (IRES) (51), a 5′-terminal genome linked protein, and a 3′-
terminal poly A tail (26).  
There are three known antigenically distinct serotypes of poliovirus, Mahoney 
(type 1), MEF-1 (type 2) and Sabin (type 3).  The entire nucleotide sequence for all three 
serotypes has been determined and the total genome consists of 7440, 7440, and 7435 
nucleotides, respectively (107). All known poliovirus isolates can be grouped into these 
three categories based on their ability to react to a reference panel of antisera. Although 
the antigenic structure of poliovirus is identical for all serotypes, each of the virus 
serotypes fails to elicit neutralizing antibodies against viruses of the other two serotypes. 
The virus displays four distinct neutralization antigenic sites on the capsid (1, 2, 3A and 
3B) that bind neutralizing antibodies (46, 68, 73). All three serotypes are capable of 
causing paralytic disease (80). In an unimmunized population, the majority of 
poliomyelitis cases were caused by type 1 poliovirus, followed by type 3, and then type 2 











































Aichi virus Gastroenteritis Human 
Teschovirus 
 
Porcine teschovirus Encephalomyelitis Pigs 
Hepatovirus 
 
Hepatitis A virus Hepatitis Human 








Table 1-1: The family Picornaviridae: genera, some representative species and the 
diseases that they cause. 
 






1.3 Epidemiology of Poliomyelitis 
Humans are the only natural reservoirs of poliovirus. The virus can be found in 
fecal-contaminated food, water, and sewage (31), although the virus does not survive 
long in the environment outside the human body.  Poliomyelitis occurs year round in the 
tropics, while it is mostly limited to summer and fall in the temperate zones. Winter 
outbreaks are rare (63). Transmission of the virus mainly occurs through the fecal-oral 
route. Oral-oral transmission is very rare. Once the virus enters the human body, it binds 
to CD155 poliovirus receptors and replicates in the pharyngeal and intestinal tract on 
follicle-associated epithelium and microfold or M cells of the Peyer’s patch (49). 
Poliovirus may be found in specimens from the oropharynx for 1-2 weeks and from the 
intestine for 3-6 weeks after infection. Shedding of the virus in the stool is intermittent 
and the degree of shedding is affected by the immune status and immunocompetence of 
the individual (27, 80). In about 1-2% of infections, the virus may enter the central 
nervous system and replicate in motor neurons causing muscle paralysis (detailed below) 
(80). A person infected with the virus is most infectious between 7-10 days before and 3-
4 weeks after onset of paralysis (2). The epidemiological pattern of the disease is 
associated with the socioeconomic development and health care services of a country. 
Crowded conditions and poor hygiene promote recurrent outbreaks of polio, thereby 
hampering global efforts to eradicate the disease.  
1.4 Pathogenesis of Poliovirus  
Upon ingestion, poliovirus infects the oropharynx and the gut, where it may cause 
mild symptoms but is often asymptomatic (14, 91). It is excreted in the oropharyngeal 





from the lymphatic tissues of the gastrointestinal tract, including the tonsils, Peyer’s 
patch of the ileum and mesenteric lymph nodes, as well as the feces, prior to the onset of 
illness (90), suggesting that susceptible cells in these tissues may be primary sites of 
replication. Following initial replication of the virus in the lymphoid tissue of the gut, 
most infected individuals develop a transient viremia with no neurological complications.  
Such infections are mainly asymptomatic. As the infection progresses further, the virus 
may spread to other sites of the reticuloendothelial system. Only about 4-8% of infected 
individuals that develop primary viremia progress to a later stage of secondary viremia 
associated with minor non-specific illness. This phase is also known as abortive 
poliomyelitis. The clinical manifestations of this nonspecific illness include a) upper 
respiratory tract infection characterized by sore throat and fever, b) a gastrointestinal 
illness characterized by nausea, vomiting, abdominal discomfort, and constipation or 
diarrhea; and/or c) headache and general malaise. Furthermore, in a small number of 
individuals who develop secondary viremia, the virus may invade the central nervous 
system, causing either non-paralytic aseptic meningitis or paralytic poliomyelitis. Non-
paralytic aseptic poliomyelitis is characterized by rigidity of the neck, lower back, and 
lower limbs in addition to increased levels of leukocytes (from 0-5 cells/mm
3
 to 10-200 
cells/mm
3
) and slightly elevated levels (from 15-45 mg/dL to 40-50 mg/dL) of protein in 
the cerebrospinal fluid. Paralytic poliomyelitis occurs in 0.1-1% of all poliovirus 
infections, depending on the specific serotype.  Paralytic poliomyelitis can be classified 
into i) spinal poliomyelitis, characterized by acute flaccid paralysis, destruction of motor 





characterized by paralysis of respiratory muscles; iii) bulbospinal poliomyelitis which 
affects both the brain stem and the spinal cord (13, 21, 63).  
There are three possible routes suggested for the spread of the virus to the central 
nervous system: (1) the circulating virus enters a peripheral nerve and is carried to the 
central nervous system by retrograde axonal transport (83) and/or (2) is able to permeate 
the blood brain barrier independent of the presence of the poliovirus receptor (113). 
Finally (3) poliovirus has been shown to replicate in primary human monocytes, 
suggesting this may be a third route for the spread of the virus from the primary site of 
infection to the central nervous system (30, 32). Poliovirus upon infection of a vaccinated 
human encounters secretory IgA present at the apical surface of mucosal epithelial cells 
and IgG and IgM in the blood stream. These antibodies complex with the invading virus 
and prevent the spread of virus via the bloodstream to target organs. Virus-antibody 
complexes are eliminated by phagocytosis, digestion, and excretion (114). The role of 
cell-mediated immunity in protection against viral infection and dissemination is less 










Figure 1-1: Poliomyelitis pathogenesis. Poliovirus infection occurs through the fecal-
oral route. The virus replicates efficiently in intestinal tract and is shed in the stool for 
two to four weeks. The lymphatic system, especially the Peyer’s patch of the ileum and 
the tonsils are invaded, and the virus enters the blood leading to transient viremia. In 
some cases, the virus enters the central nervous system and replicates in the motor 
neurons within the spinal cord and brain stem and causes muscle paralysis. Figure 
adapted from Blondel, B., Colbere-Garapin, F., Couderc, T., Woritius, A., Guivel-






1.5 Vaccines against Poliovirus  
 Two different types of polio vaccines have been developed: Jonas Salk’s formalin 
inactivated polio vaccine (IPV) and Albert Sabin’s live, attenuated oral polio vaccine 
(OPV). Widespread immunization with IPV and OPV led to the eradication of polio from 
developed countries. IPV was the first polio vaccine to be licensed and is prepared by 
formalin-inactivation of three wildtype, virulent reference strains: Mahoney (type 1), 
MEF-1 (type 2), and Saukett (type 3). IPV was licensed for use in the United States, 
Canada, and Western Europe in 1955 and was the only polio vaccine available until 
licensure of OPV in 1961–1962.  IPV is administered as an intramuscular injection and 
confers IgG immunity in the blood stream against all three strains of the virus. These 
antibodies prevent the progression of the infection to viremia and spread of virus to the 
central nervous system (54). Since IPV contains inactivated strains of poliovirus, it 
cannot cause poliomyelitis and is safe for use in immunocompromised people. One of the 
disadvantages of IPV is that it can only be administered by injection. This increases the 
effective cost of vaccination, which is a major concern in developing countries. The IPV 
also induces a lower level of gastrointestinal immunity (63).  This protects the individual 
from paralytic poliomyelitis but cannot curtail the spread of virus to other people. 
OPV consists of a mixture of live, attenuated poliovirus strains of each of the 
three serotypes that are able to mimic the immunological response to a wild type 
poliovirus infection. They are less neurovirulent and therefore are unable to spread to the 
central nervous system.  Like IPV, OPV also produces antibodies against all three strains 
of the virus, which protects the individual in the event of an infection. It also produces a 





the intestine. This additional immune response protects the individual from any incoming 
poliovirus infection. OPV confers passive immunity to people who have not been 
vaccinated. For several weeks post vaccination, the vaccine virus replicates in the gut and 
is excreted in the feces and can spread to people in close contact. OPV is more cost 
effective compared to IPV, as it is administered in the form of drops by mouth and can be 
given by volunteers without the additional requirement of healthcare workers, needles, or 
syringes. OPV remains the vaccine of choice in areas where wild poliovirus is endemic, 
but has been replaced with IPV in many countries where polio has been eradicated (70) 
1.6 The Poliovirus Endgame 
Since its launch in 1988, the Global Polio Eradication Initiative (GPEI) has come 
very close to its long term goal of a polio-free world.  Polio existed in 125 countries 
across the globe in 1988 and by 2006 just four countries remained endemic. Of the four 
countries, India was recently declared as a polio-free nation (7). The remaining three 
countries i.e., Pakistan, Afghanistan and Nigeria are taking vigorous steps to stop the 
transmission of wild type poliovirus, mainly strains 1 and 3. In 1999, the GPEI achieved 
a major milestone of successfully eradicating type 2 poliovirus, leaving only the lab 
stocks for vaccine research. Unfortunately, ten years later in 2009 a new form of type 2 
poliovirus emerged in Nigeria (85). 
One of the main problems encountered on the road to polio eradication is the 
imperative use of oral polio vaccine in endemic regions. The risk associated with OPV is 
that, in rare cases (1 in 2.6 million doses), the genetically modified vaccine virus reverts 
via mutations or recombination to a more neurovirulent form while replicating in the gut, 





are capable of person-to-person transmission, these unattentuated vaccine-derived 
polioviruses (VDPVs) can spread by person-to-person contact as well. For any given area 
to be remain polio free, it is necessary to eliminate indigenous wild type poliovirus 
transmission, control the importation of wild type poliovirus cases, and adopt a change in 
vaccine policy (i.e., from live, attenuated oral polio vaccine [OPV] to inactivated polio 
vaccine [IPV]) to eliminate the possibility of VAPP cases. 
The final push towards eradication is at its peak but factors such as war, poverty, 
political instability, and isolated communities decrease the efficiency of widespread 
immunization programs required to block the spread of the virus. The recent successful 
eradication effort in India gives hope to the overall goal of a polio-free world. In early 
2012, India was removed from the list of polio-endemic countries after it went without 
reporting a single case of polio in a span of one year. Since India was considered a hotbed 
for polio, this milestone is a big motivator for the remaining countries to make the final 
push towards eradication (53, 54). 
1.7 Poliovirus Structural Characteristics 
 
Poliovirus is a non-enveloped virus made up of capsid proteins enclosing a single-
stranded RNA genome. The capsid is an icosahedron (45) that consists of 60 copies of 
each of the proteins VP1, VP2, VP3, and VP4, which are produced by proteolysis of a 
viral polyprotein (Figure 1-2). The capsid precursor P1 is cleaved into VP0, VP3, and 
VP1, which remain associated as protomerss but rapidly aggregate to form pentamers 
[(VP0, VP3, VP1)5]. Twelve pentamers, in turn, assemble to form the "procapsid" [(VP0, 
VP3, VP1)5]12. It is unclear if the viral RNA is inserted into an empty capsid or if the 





the cleavage of VP0 to VP4 and VP2 (43). The three large capsid proteins (VP1, VP2, 
and VP3; ~ 30 kDa) are folded into eight-stranded, antiparallel beta barrels, a pattern that 
is highly conserved among eukaryotic RNA viruses (87). The smaller, myristoled capsid 
protein VP4 (7 kDa), lines the inside of the capsid (19). The amino acid loops that join 
the beta strands in the beta barrel structures constitute the neutralizing antigenic sites of 
the virion. There are four major neutralizing sites on the poliovirus. There are only three 
unique sets of these four antigenic sites hence there are only three serotypes of poliovirus; 
type 1, type 2 and type 3. Antibodies elicited against any one type are unable to neutralize 
the infectivity of the other two types (46, 65).  
1.8 Poliovirus Genetic Organization and Protein Functions 
The poliovirus type 1 (Mahoney) genome consists of a single copy of plus-sense 
single-stranded RNA which is approximately 7.5 kb long. The genome has a relatively 
long, highly structured 5' non-translated region (NTR) of 742 nucleotides with a 
covalently linked 22 amino acid peptide primer referred to as VPg or 3B at the 5' 
terminus. The 5' non- translated region contains sequences that control genome 
replication and translation. It contains a terminal clover-leaf structure that is 
indispensable to replication regulating initiation of translation. It also contains the 
internal ribosome entry site (IRES) that directs cap-independent translation of viral 
mRNA by internal ribosome binding. The 3' NTR at the other end is relatively short (70 
nucleotides) and is followed by a polyA tail of 60 residues (21). The 3' NTR also contains 
secondary structures, including a pseudoknot that has been implicated in controlling viral 
RNA synthesis (50). Deletion of the 3' NTR has minimal effects on the propagation of 





cells of neuronal origin in vitro and in vivo (16). Between these two regions lies a single 
open reading frame that codes for a 250 kDa polyprotein of 2209 amino acids. The 
polyprotein is processed into various precursor proteins and stable processed proteins by 





















Figure 1-2: Genomic structure of poliovirus type 1 (Mahoney strain) and proteolytic 
processing of its polyprotein. The poliovirus genome consists of a single stranded, 
positive sense RNA molecule encoding a single polyprotein. The 5ʹ NTR harbors two 
functional domains, the cloverleaf structure and the IRES, and is covalently linked to a 
short highly basic protein, 3B (VPg). The 3ʹ NTR has a pseudoknot structure and a poly 
A tail. The polyprotein derived from the single mRNA transcript is cleaved by virus 
encoded proteases into ten fully processed proteins in addition to various intermediate 









Table 1-2: Properties and functions of proteins encoded by the P3 region of the poliovirus genome 
Protein Properties and functions 
3A Required for RNA replication 
 Membrane associated  
 Inhibits host protein secretion 
 Substrate for glycoslysation 
 Interacts with 3AB 
 Dimerizes 
  
3B Required for RNA replication 
 Covalently linked to plus- and minus- strand RNA 
 Substrate for uridylation 
 Weakly stimulates 3D activity in vitro 
 Weakly stimulates 3CD
pro
 autoprocessing 








 Processes viral proteins 
 Cleaves host proteins 
 Weakly binds to 5′ cloverleaf with 3AB 
  
3Dpol Required for RNA replication 
 Uridylylates Vpg 
 Elongates RNA chains 
 Unwinds double stranded RNA during 
polymerization 
 Binds to RNA 
 Has terminal adenylyltransferase activity 
 Can switch templates 
 Interacts with cellular protein Sam68 
 Interacts with 3CD
pro
, 3B, 3AB 
 Dimerizes 
  
3AB Required for RNA replication 
 Associated with membranes 
 Binds to RNA (nonspecific) 
 Binds to 5′ cloverleaf structure with 3CD
pro
 
 Binds to 3′ NTR with 3CD
pro
 or 3Dpol 
 Substrate for gyclosylation 
 Stimulates 3D
pol
 activity invitro 
 Stimulates 3CD
pro
 autoprocessing invitro 







3CD Required for RNA replication 
 Processes viral proteins 
 Processes cellular protein 
 Binds to 5′ cloverleaf with PCBP2 
 Interacts strongly with 3B, 3AB 
 Interacts weakly with 3Dpol, 3CD
pro
 
 Binds to 3′ NTR with 3AB 






1.9 Life Cycle of Poliovirus 
 
The life cycle of the poliovirus is divided into four main steps (Figure 1-3)  
1. Virus attachment and entry:  Replication of poliovirus is initiated by attachment 
of the virus to its cognate receptor, CD155, found only on the surface of primate 
cells. The human poliovirus receptor belongs to the immunoglobulin superfamily 
and may function as a cell-adhesion molecule (64). Once the virus particle is 
internalized by either receptor-mediated endocytosis or through pore formation in 
the cell membrane, the genome is injected into the cytoplasm through vesicles 
located very close to the plasma membrane (34, 61). Within the host cell, the 5' 
NTR linked viral protein VPg may be cleaved by an unknown host cell 
phosphodiesterase termed VPg unlinkase (38, 89), although the enzyme causing 
the cleavage still remains controversial. The poliovirus genomic RNA now serves 
as an mRNA ready to be translated.  
2. Protein synthesis: The host translational machinery binds to a highly structured 
RNA cis-acting element termed the internal ribosome entry site (IRES). The 
absence of a 7-methyl guanosine cap structure at the 5' end of the genome results 
in cap-independent translation of the polyprotein via the IRES. This polyprotein is 
co- and post-translationally cleaved into three main precursor proteins, P1, P2 and 








The P1 region 
encodes capsid proteins, VP1-VP4, while the P2 region encodes non-structural 
proteins (2A
pro
, 2B, 2BC and 2C
ATPase
) that induce biochemical and structural 





RNA synthesis. They include highly stable precursor proteins 3AB and 3CD
pro
 
that function in replication and may also be further processed into mature proteins 




 (21). These viral proteins cause disruption of a 
number of cellular functions, including inhibition of host-cell transcription and 
translation and the rearrangement of the host-cell endoplasmic reticulum to form 
membranous vesicles throughout the cytoplasm (17, 112). 
3. RNA replication: With the synthesis of viral proteins, the virus now begins its 
replication process (Figure 1-3). Replication is believed to take place on the 
surface of host-cell endoplasmic reticulum derived rosette-like membranous 
structures, the formation of which is induced by viral encoded proteins 2BC and 
2C (12). A replication complex comprised of the genomic RNA, viral proteins, 
and cellular proteins (Figure 1-4) is formed on the membranous structures that 
help increase the local concentration of these components and provide a scaffold 
for the assembly of the complex. 3AB is thought to associate with these 





 owing to its affinity for these proteins. Genome replication is initiated by 
3D
pol
 catalyzed uridylation of VPg. Uridylated VPg (Vpg-pU-pU) serves as a 
primer for negative strand synthesis, which results in a double stranded RNA 
known as the replicative form, RF. The RF is continuously formed during 
infection at a relatively low rate and is generally believed to be an intermediate of 
replication rather than an artifact of isolation procedures (59). Positive strands 





negative strand produces many new positive strands in a complex called a 
replicative intermediate (RI). 
Negative strands are always associated with either the RF or RI and are never 
found free in the cell. The newly synthesized positive strand RNA can be used as 
templates for further translation of proteins or can associate with capsid 
precursors to undergo encapsidation, forming progeny virions that are then 
released upon lysis of infected cells (21). 
4. Packaging and release: Encapsidation of Vpg - linked positive strand RNA 
molecules appears to be linked to RNA synthesis at the interface of membranous 
structures in the cytoplasm of infected cells. The capsid proteins VP0, VP1 and 
VP3, formed as a cleavage product of the P1 region of the polyprotein, assemble 
as promotmers to form pentamers. Twelve pentamers constitute a procapsid. The 
VPg - linked genomic RNA maybe encapsidated by condensation of pentamers 
about the viral RNA or by incorporation of viral RNA into the capsid.  The final 
step involves the autocatalytic cleavage of VP0 into VP2 and VP4 that stabilizes 
the capsid and converts the provirion into a mature virus particle.  Subsequent 
lysis of the infected cells leads to the release of mature virions of which about 1% 










Figure 1-3: Schematic representation of the cellular life cycle of poliovirus. The 
cellular life cycle of poliovirus is initiated by binding to its cognate receptor CD155. 
Uncoating of viral RNA is followed by cap-independent translation giving rise to various 
proteins upon polyprotein processing. These proteins are utilized for positive-sense RNA 
synthesis which is formed from a negative strand intermediate. The newly synthesized 
positive strands can serve as templates for translation or associate with capsid proteins to 
undergo encapsidation and induce maturation cleavage of VP0, ultimately generating 
progeny virions. Lysis of the infected cell results in release of infectious progeny virions. 






Figure 1-4: Schematic representation of poliovirus replication complex on 
membrane vesicles. Poliovirus replication occurs on the surface of intracellular 
membrane vesicles which, are induced by virus encoded proteins, mainly 2C
pro
 and 2BC. 
3AB is thought to anchor the replication complex on the surface of membrane vesicles 
via its hydrophobic domain. 3AB interacts with other P3 proteins to form protein-protein 
bridges that allow non-RNA binding proteins required for replication, to interact with 
RNA. For example 3CD binds to 5' NTR in the presence of 3AB along with a cellular 
factor, Poly (C)-binding protein, (PCBP). Poly (A)-binding protein, (PABP), also a 
cellular factor, binds to the 3ʹ NTR which in turn interacts with the 5' NTR. This leads to 
genome circularization that brings the viral polymerase 3D
pol
 in close proximity of the 3ʹ 
poly A tail and allow for initiation of negative strand synthesis. Figure taken from Paul, 





1.10 Poliovirus Protein 3AB and its Role in Poliovirus Replication 
Poliovirus 3AB is a 12 kDa protein with a hydrophobic 3A region (N-terminal 87 
amino acids) and a highly basic 3B (VPg) region (C-terminal 22 amino acids). It is 
formed as a cleavage product of an 83 kDa precursor protein encoded by the P3 region of 
the viral genome, which in turn is derived from a 247 kDa viral polyprotein translated by 
a single open reading frame mRNA transcript (Figure1-2). 3AB is a multifunctional 
protein and one of the key players of the viral replication process. Infection of cells with 
poliovirus leads to accumulation of new membrane vesicles derived either from 
intracellular organelle rearrangement or de novo membrane synthesis. These rosette-like 
membranous structures support the viral replication complex on their surface, similar to 
what occurs in other plus sense RNA viruses. 3AB is thought to anchor the replication 
complex on these membrane vesicles through the hydrophobic domain in the 3A region 
of 3AB (35). 
 3AB interacts with other P3 proteins to form protein-protein bridges that allow 
non-RNA binding proteins required for replication, to interact with RNA. For example 
3CD binds to the 3' and 5' non-translated region in the presence of 3AB (40, 111). 





 and allows the membrane-associated 3AB to be cleaved to produce 3A and 3B 
(66). It has been shown that the processing of 3CD requires membrane bound 3AB (56). 
3AB by itself is a non-specific RNA binding protein but in the presence of 3CD binds 
specifically to the 5' end of the genome (40, 111). 3AB also binds to 3D
pol 
and helps 





synthetic activity of 3D
pol
 in vitro, especially when low concentrations of the polymerase 
are used (57, 76, 79, 84, 86).  
 3AB is cleaved to 3A and 3B by 3CD
pro
. 3A is a critical component of the 
replication complex and is a putative target of enviroxime, an antiviral drug that block 
viral replication (42). 3A inhibits host cell endoplasmic reticulum – Golgi apparatus 
transport, a function that may play a role in viral evasion from the host immune system 
(24, 25, 71). Although 3A differs from its precursor 3AB by 22 amino acids, the two 





 in vitro; however mutations in the 3A region of 3AB produce replication-
deficient viruses. The solution structure of a truncated form of 3A reveals that it is a 
homodimer, with the internal region of each mononmer adopting a helical hairpin fused 
to unstructured N- and C-termini (98).  
 3B (VPg) is covalently attached to all newly synthesized plus and minus strand 
RNAs via a phosphodiester bond between the conserved tyrosine residue at position 3 
(Y3) of VPg and the terminal UMP in the RNA genome (3, 88). The uridylated form of 
this protein serves as a primer for RNA synthesis (74). Two uridine residues are added to 
the tyrosine residue, Y3, of VPg, in a reaction catalyzed by 3D
pol
 using a template 
referred to as CRE (cis-acting replication element) located in the 2C region of the 
genome (77, 97). Uridylated VPg is then transferred to the 3ʹ end of the genome or minus 
sense copy of the genome by an unknown mechanism, and is extended by 3D
pol
 to initiate 






1.11 Nucleic acid chaperone proteins 
Nucleic acid chaperones are proteins that assist in folding nucleic acids to their 
biologically active and thermodynamically most stable conformations by resolving 
misfolded structures and kinetically trapped species (44, 81, 119). They do so by 
lowering the energy barrier for breakage and re-formation of base pairs. The interaction 
of a nucleic acid molecule with a chaperone protein results in transient unpairing of bases 
within the chain, making them available for repairing in alternate combinations (82). 
Nucleic acid chaperone possess weak helix destabilizing (unwinding) activity that 
disrupts secondary structures and promote the annealing of complementary nucleic acids 
strands. Some chaperones can drive the formation of nucleic acid aggregates in vitro, thus 
further enhancing hybrid formation (20, 44). These activities of chaperone proteins are 
thought to encourage efficient viral genome replication within the host. Exactly how this 
occurs in vivo has not been established. The multifunctional and ubiquitous nature of 
chaperone proteins has made it difficult to assign discrete activities using standard 
genetic mutation based approaches. For plus sense viruses chaperone activity could be 
involved at several stages of the viral life cycle including: helping 3D
pol
 traverse the 
highly structured genome, promoting recombination, and facilitating structural switches 
that may be important for the genome to function in translation, replication and 
packaging (Figure 1-5). 
 The helix destabilizing activity of a chaperone protein can be explained by the 
entropy transfer model. According to this model, a chaperone protein that is predicted to 
have a region of disorder, unwinds secondary structures and refolds them into their 





Figure 1-7) (119). Highly flexible regions of the protein undergo disorder to order 
transitions upon binding to the RNA, melting secondary structures within the RNA 
through entropy exchange process. The destabilized RNA could now adopt its most 
stable conformation. The interaction between the chaperone protein and the RNA is 
thought to be transient and non-specific. These proteins have to presumably get on and 
off to allow RNAs to fold properly and retain structure.  
Chaperone proteins are known to promote hybridization of complementary 
nucleic acids. They destabilize weak secondary structures without the use of ATP 
hydrolysis and promote aggregation of complementary strands either by directly 
promoting binding or by reducing charge repulsion by coating nucleic acid strands (60). 
It has been well established that 3AB promotes hybridization of complementary nucleic 
acids in the absence of nucleotides (as an energy source). Hybrid formation is 
concentration-dependent and requires enough 3AB to at least partially coat nucleic acid 
strands (23). 3AB’s chaperone function is similar to other chaperone proteins, such as 
human immunodeficiency virus nucleocapsid protein (HIV NC) and heterogenous 
nuclear ribonucleoprotein A1 (hnRNP A1). Both HIV NC and hnRNP A1 are known to 
bind and coat nucleic acids. HIV NC displays both specific as well as non-specific 
nucleic acid binding. The helix destabilizing activity of NC appears to be due to the 
physical binding of NC’s zinc fingers to the unpaired bases of nucleic acids strands 
whereas the formation of nucleic acid aggregates is facilitated by coating nucleic acid 
strands and reducing inter-strand repulsion. The formation of nucleic acid aggregates 
increases the probability of finding complementary strands and facilitates the nucleation 





of hybridization between complementary sequences (60). Nucleic acid chaperone 
proteins tend to be positively charged. HIV NC has 16 positively charged amino acid 
residues out of a total of 55 while 3AB has not zinc fingers and only 14 positively 
charged amino acid residues out of its 109 total amino acids. In 3AB, these charges are 
grouped into discrete clusters at the amino and the carboxyl terminal regions. Mutations 
of positively charged bases at the carboxyl terminal region (3B region) greatly affect 
binding to RNA and stimulation of 3D
pol
. Therefore, this region is very important to RNA 
binding as well 3AB/3B-3D
pol
 interactions (115). While chaperone proteins do not have a 
conserved motif that defines their activity, most of them are known to have intrinsically 
disordered domains, i.e. a cluster of amino acids that do not have a well-defined 
conformation under physiological conditions in vitro (102). These flexible regions 
probably allow the proteins to bind to a wide range of nucleic acid structures and 
sequences as well as promote rapid association and dissociation with target molecules. 
Based on GlobProt, an online program for predicting disordered protein regions, 3AB has 










Figure 1-5: Possible roles for chaperone activity in poliovirus/picornavirus 
replication. A schematic representation of the poliovirus genome along with important 
secondary structures in the non-translated regions is shown. Possible roles of 3AB or 









Figure 1-6: Predicted disordered domain of PV 3AB protein using GlobProt: Virus 
encoded chaperone proteins do not share a common domain or motif but display a high 
degree of disorder, suggesting that disorder might be a mechanistic requirement for 
chaperone activity. According to this prediction, a region of disorder lies in the N-
terminus of 3A region and the entire 3B region (indicated in blue). Our results indicate 
that 3B region does not possess chaperone activity by itself but is required for chaperone 
activity of 3AB (Chapter 2). It is possible that the disordered region of 3B contributes to 
the chaperone function of the 3AB. Figure generated using GlobProt intrinsic disorder 







Figure 1-7: Model for RNA chaperone mechanism based on entropy transfer. A 
fully disordered RNA chaperone (red) binds to a partially misfolded substarte RNA in a 
non-specific manner. Disordered domains of the protein become ordered while domains 
of RNA are unfolded (entropy transfer from protein to RNA). The RNA is correctly 
folded while the protein becomes disordered again (entropy transfer from RNA to 
protein). The correctly folded RNA is released after multiple cycles of order-disorder, 
and the chaperone protein is free to act again. This process occurs in the absence of  ATP 







1.12 Chaperone proteins in viruses 
The first reported viral chaperone was the HIV NC protein in 1988. Since then the 
list of chaperones among viruses has been growing rapidly leading to an increased 
interest in this field. The most well studied viral chaperone protein is HIV NC. As a 
chaperone protein NC facilitates dimerization of genomic RNA, initiation of reverse 
transcription, strand transfer (template switching) events during reverse transcription, and 
also promotes recombination. In addition, NC is required for packaging, tRNA 
association with the genome for initiation of replication, and possibly integration of the 
proviral DNA (60). This illustrates the difficulty in assigning specific functions to this 
chaperone as single mutations may affect several protein functions. Some host proteins 
like hnRNP A1, also possess chaperone function that is thought to be essential for viral 
RNA synthesis. Interestingly, while chaperone proteins occur in many species, they do 
not share any common motifs or conserved sequence. Also, chaperone proteins from the 
same virus genus have little sequence similarity (119). Table 1-3 lists the chaperone 
proteins found in viruses to date. 
The goal of the study is to identify what regions of 3AB are intrinsic to chaperone 
activity and to test the effect of mutations in the putative chaperone domain on replication 















Virus Encoded   
NC Retrovirus  Reverse Transcription, 
Template switch 
SdAg HDV Replication 
Core Flaviviridae Replication 
N Coronavirus RNA synthesis 
N Hantavirus Replication 
3AB Poliovirus Replication, Recombination 
Vif HIV-1 Temporal regulation of 
reverse transcription 
Tat HIV-1 Viral DNA transcription 
   
Host Factors   
PTB Picornavirus, HCV, 
Coronavirus, Calicivirus 
Translation, RNA synthesis 
hnRNP A1 Coronavirus RNA synthesis 
La HCV, Poliovirus Translation, Replication 
Unr HRV-2 Translation 
PARBP33 ASBVd Replication 
a NC, nucleocapsid protein; SdAg, small delta antigen; N, nucleocapsid protein; Vif, viral infectivity 
factor; Tat, transcription activation factor; PTB, polypyrimidine tract binding protein; hnRNP A1, 
heterogeneous nuclear ribonucleoprotein A1; Unr, upstream of N-ras. 
b HDV, hepatitis delta virus; HIV-1, human immunodeficiency virus-1; HCV, hepatitis C virus; HRV-2, 
human rhinovirus-2; ASBVd, avocado sunblotch viroid. 










Chapter 2: The C terminal cytoplasmic domain of 3AB is intrinsic 
to the chaperone activity of 3AB 
2.1 Introduction 
Poliovirus replication involves complex secondary structures at the viral genome 
terminal regions, and both host and viral proteins. Replication occurs on the surface of 
intracellular membrane vesicles derived from the ER (11). 3AB is an integral part of the 
viral replication machinery as it anchors replication complexes to internal cellular 
membranes, interacts with several proteins required for genome replication and 
stimulates the viral polymerase (3D
pol
) in vitro (reviewed in section 1.10).  Details of the 
mechanism(s) by which 3AB accomplishes these functions remain vague. 3AB is a small 
hydrophobic protein with a membrane-binding region near the C-terminus of its 3A 
region. It has been shown to possess biochemical characteristics of an integral membrane 
protein (103). 3AB is proteolytically cleaved by 3C/3CD viral proteases to yield 3A and 
3B (VPg) (56). The 3A protein is 87 amino acids in length, consisting of a soluble N 
terminal domain that forms a symmetrical dimer in solution (58 residues), a 22 amino 
acid hydrophobic domain (59-81) followed by seven amino acids at the C-terminus. The 
hydrophobic domain is subdivided into two domains (I, aa 64-72 and II, aa 73-80), the 
latter being the main membrane-anchoring determinant. The first 15 amino acids of the 
hydrophobic domain are predicted to form an amphiphatic helix. Even though the 
membrane association of protein 3A and 3AB has been known for years, the precise 
arrangement of these proteins in the hydrophobic lipid environment remains unclear 





membranes forming a non-trans membrane configuration while the soluble regions of 3A 
and 3B (VPg) remain on the same cytosolic side (35). 
In 2006, our lab showed that bacterially expressed purified 3AB protein possesses 
properties consistent with chaperone proteins - i.e. helix destabilizing activity and 
promotion of hybridization of complementary nucleic acids in the absence of nucleotides 
(as an energy source) (23) classifying 3AB as a nucleic acid chaperone. The effect was 
nonspecific as enhancement of annealing occurred for both RNA and DNA and even 
highly structured nucleic acids could be annealed. Hybrid formation was concentration-
dependent and required enough 3AB to coat the nucleic acid strands. Conditions for 
optimal activity were established and included low divalent cation (1 mM Mg
2+
) and salt 
(20 mM KCl) concentrations although 3AB also showed modestly reduced chaperone 
activity with higher more physiological salt concentrations.   
In the current report we show that the 3B region of 3AB is necessary but not 
sufficient for chaperone activity as specific mutations in this domain abolish chaperone 
activity while 3B alone has no chaperone activity even at very high concentrations.  
Interestingly, the putative C-terminal cytoplasmic domain of 3AB, consisting of 3B and 
the last 7 amino acid at the C-terminal end of 3A (termed 3B+7 in this report), does have 
chaperone activity at high concentrations.  These results form the basis of a working 








                                                                                                                                      
Figure 2-1: Amino acid sequence of 3AB. Amino acids 1-58 make up the 3A region of 
3AB. The bolded letters indicate the hydrophobic region (amino acids 59-80). VPg or 3B 
is indicated by letters in red (amino acids 88-109). The table below indicates the different 
domains or regions of 3AB. 
 
Region Amino acids 
3AB 1 – 109 
3A 1 – 87 
3B (VPg) 88 – 109 
Hydrophobic membrane anchor sequence 59 – 80 
C-terminal cytoplasmic domain of 3AB 81 – 109 
Connection domain 81 – 87 

















2.2 Materials and Methods 
2.2.1 Materials  
T3 RNA polymerase, calf intestinal phosphatase (CIP), DNase I (RNase free), and 
ribonucleotides, were obtained from Roche Applied Science. RNasin was obtained from 
Promega, restriction enzymes and T4 polynucleotide kinase from New England Biolabs 
and Proteinase K from Stratagene. All synthetic oligonucleotides were custom – ordered 
from Integrated DNA technologies Inc. (IDT). Chemically synthesized proteins including 
3B, 3B+7, and all 3B+7 proteins with mutations were from GenScript Inc. and were of 
90% purity or greater. Point mutations in 3AB were made using the Quickchange 
Lightening Site-Directed Mutagenesis kit from Agilent technologies. Sephadex G-25 spin 
columns were from Harvard Apparatus. RNeasy mini kits were from Qiagen Inc.  
Radiolabeled compounds were from Perkin Elmer. All other chemicals were obtained 
from Sigma Chemical Co., Fisher Scientific, or VWR scientific. 
2.2.2 Methods 
Preparation of recombinant proteins poliovirus 3AB and HIV NC by 
expression in Escherichia coli. Protein 3AB of poliovirus type 1 (Mahoney strain) and its 
mutant forms 3AB-Y90A, 3AB-R104E and 3AB-Y90A/R104E were expressed in E. coli 
using plasmid pGEX-3AB, kindly provided by Dr. Stephen Plotch (formerly of Wyeth-
Ayerst Research). Mutagenic primers for 3AB mutations are listed in Table 2-2. 
Expression and purification was performed as previously described (79). Purified 3AB was 
stored at -80
o
C in buffer containing 50 mM Tris-HCl (pH=8), 1 mM DTT, 0.05% Triton X-





provided by Dr. Charles McHenry (Univ. of Colorado). The protein was expressed in E. 
coli and purified as previously described (116). 
Preparation of mutant forms of poliovirus 3AB with point mutations in the 
connection domain. Protein 3AB has a tendency to form insoluble aggregates/inclusion 
bodies during protein purification. We experienced difficulty using the pGEX expression 
system used for wildtype 3AB and specific mutants noted above. Although expression 
was successful, nearly all of the truncation and connection domain mutants formed 
insoluble aggregates. This was not resolved using various detergents and expression 
temperatures. SUMO-based expression systems have been reported to greatly aid in the 
expression of difficult proteins. We were successful in optimizing expression and 
purification of SUMO tagged wildtype 3AB and mutant forms of the putative C-terminal 
cytoplasmic domain of 3AB. Mutagenic primers for 3AB mutations are listed in Table 2-2.   
E.coli BL21[DE3] containing pSUMO-3AB was grown at 37°C in one liter 2xYT broth 
containing 40µg/ml Kanamycin to an optical density at 600 nm of 0.6 at which time IPTG 
(isopropylthiobetagalactoside) was added to a final concentration of 0.25mM. After 4h at 
30°C cells were harvested by centrifugation and the pellet was either stored at -80°C or 
suspended immediately in 20 ml of 50 mM Tris-HCl pH 7.0, 200 mM NaCl, 1 mM DTT, 
0.1% Triton X-100 and 10% glycerol (buffer I) per liter of original culture. The suspension 
was sonicated at 0°C using a Branson sonifier 450 with a tapered microtip (setting 6, 50% 
duty cycle) pulsing 6 x 30 seconds with 30 second intervals. The lysate was centrifuged 
at 25,000 x g for 20 min. The pellet was re-extracted in 10 ml of buffer I containing 1M 
NaCl. The lysate was centrifuged as before and the obtained supernatant was diluted 





with 3.0 ml of PerfectPro Ni-NTA agarose resin (5 PRIME) equilibrated in buffer I. After 
incubating for 2.5h at room temperature, the agaorse gel was washed with 50 column 
volumes (75 ml) of buffer I + 10 mM imidazole. The SUMO-tagged protein was eluted in 
4 ml buffer I + 300 mM imidazole and dialyzed for several hours against one liter of 50 
mM Tris-HCl pH 7.0, 30 mM NaCl, 1.0 mM DTT, 0.1% Triton X-100 and 10% glycerol 
(buffer A) at 4°C in presence of 50 units of SUMO protease 1. Any precipitate was 
removed by centrifugation and clear supernatant was loaded onto a 5 ml mini profinity 
IMAC Ni cartridge pre-equilibrated with buffer A using a Bio-Rad Biologic DuoFlow 
FPLC. After being washed with 10 ml of buffer A, the column was developed with a 25 
ml linear gradient of 30 mM to1 M NaCl in buffer A. Fractions were analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and assayed for 
unwinding activity by FRET (see below). The protein minus the SUMO tag elutes at low 
salt concentrations while the SUMO tag, which contains a histidine nickel binding 
sequence, remains bound to the column. Fractions containing untagged 3AB were 
aliquoted and stored at -80°C.  
5' end-labeling of oligonucleotides. Reactions for primer labeling were done in a 
50 µl volume containing 70 mM Tris-HCl, pH=7.6, 10 mM MgCl2, 5 mM DTT, 10 µl of 
γ-
32
P ATP (3000 Ci/mmol, 10 µCi/µl) and 2 µl (20 units) of T4 polynucleotide kinase.  
The reaction mixture was incubated for 30 minutes at 37
o
C and then the T4 
polynucleotide kinase was heat inactivated for 10 minutes at 70
o
C according to 
manufacturer’s recommendation. The material was then run through a Sephadex G-25 





Preparation of RNA templates. Run-off transcripts were synthesized with T3 
RNA polymerase using the manufacturer's protocol. Plasmid pBSM13+ was cleaved with 
Bgl I or Nde I was used to prepare run-off transcripts ~230 or 765 nucleotides in length, 
respectively. After transcription for 2 hours, 15 units of DNase I (RNase-free) was added 
and incubation was continued for 20 min. Reactions were then processed with a RNeasy 
mini kit according to the manufactures’ protocol. The length and purity of the RNA was 
evaluated by gel electrophoresis to assure that it was full-length (data not shown). The 
RNA was then quantified by spectrophotometric analysis. The equation used to calculate 
the molecular weight was: ([A x 382.2] + [G x 344.2] + [C x 304.2] + [U x 305]). The 
molecular weight was used to calculate the molar concentration of RNA using the 




40 µg/ml for single stranded RNA.   
Fluorescence resonance energy transfer (FRET) unwinding assay. Two 
complementary 42 nucleotide DNAs, one with a 5’ fluorescein-6-carboxamidohexyl 
(FAM) (FAM-CAT TAT CGG ATA GTG GAA CCT AGC TTC GAC TAT CGG ATA 
ATC-3') group and the second with a 3’ 4-[[(4-dimethylamino)phenyl]-azo] 
benzenesulfonicamino (DABCYL) group (5'- GAT  TAT CCG ATA GTC GAA GCT 
AGG TTC CAC TAT CCG ATA ATG-3'- DABCYL) were used in the assays. Using 
mfold(118) and conditions of 20 mM KCl, 1 mM MgCl2, and 30
o
C, each strand was 
predicted to form a stem-loop structure with a ΔG value of -7.2 kcal/mol (Fig.).  
Annealing assays were completed at 30
o
C using a Cary Eclipse fluorescent 
spectrophotometer (Varian). FAM and DABCYL DNAs (10 and 20 nM, respectively.) 
were separately incubated for 5 min at 30
o
C in the presence or absence of 3AB or other 





(pH=7), 20 mM KCl, 5 mM DTT, 1 mM MgCl2, 6 mM Tris-HCl (pH=8), 0.014% Triton 
X-100, and 2.9% glycerol. The reactions were started by mixing the FAM and DABCYL 
samples in a quartz cuvette (final concentrations 5 and 10 nM, for FAM and DABCYL 
DNAs, respectively). The excitation wavelength was 494 nm with a bandwidth of 5 nm.  
The emission bandwidth was 10 nm and the spectrum was observed at 520 nm. The 
emission spectrum was taken every 15 seconds for up to 16 minutes. An intensity ratio 
(Ir) was determined by dividing the peak intensity at a given time (It) by the peak 
intensity at time zero (I0) (Ir = It/I0). This value was plotted versus time for the different 
concentrations of protein used. For some proteins rate constant values (k) describing the 
rate of annealing for the complementary strands were calculated. These values were 
calculated from the t1/2 values by dividing 0.693 by t1/2 as described.(117)    
Primer-template annealing assay. The 230 nucleotide RNA transcript (10 nM 
final concentration) (described above), and a 25 nucleotide complementary 5ʹ 
32
P-labeled 
RNA oligonucleotide (10 nM final concentration, 5'-CCU CUU CGC UAU UAC GCC 
AG -3’) that hybridized to based 155-179 from the 5’ end of the transcript were incubated 
in 50 mM HEPES (pH=7), 5 mM DTT, 1.4 mM MgCl2 and 28.5 mM KCl. This material 
was pre-incubated for 3 mins at 30
o
C in 7 µls total volume. Three µls of 3AB or other 
derivatives (concentration as indicated) or 3AB buffer (see above) was added after the 
pre-incubation to start the reaction which was continued for 15 minutes. One µl of 
proteinase K (final concentration 1 µg/µl) in 10 mM Tris-HCl pH=8, 50 mM EDTA 
pH=8 was then added to each sample and incubation was continued for 10 minutes at 
37
o
C.  After this, 5 μls of stop mix (20% glycerol, 20 mM EDTA pH=8, 0.2% SDS, 0.4 





control contained the pre-incubated reaction and 3AB buffer and was heated at 65
o
C for 5 
mins and then slow cooled. This control was used to show where the hybrid migrated on 
the gel. A second control contained BSA (final concentration 0.1 µg/µl) in 3AB buffer 
instead of 3AB. All controls were processed as above. Products were analyzed on a 6% 
native polyacrylamide gel as describe below. Dried gels were exposed to an imaging 
screen and visualized and quantified using a Fujifilm FLA-7000.   
Gel-shift assay to test nucleic acid binding. A 40 nucleotide 5ʹ 
32
P-labeled RNA 
(2 nM final concentration, 5ʹ-GAG UGC ACC AUA UGC CAU UCA GGC UAC GCA 
ACU GUU GGG A -3’) was mixed with different amounts of 3AB or other proteins (see 
Fig. 5) in 10 µl of a buffer containing 10 mM HEPES pH=7, 5 mM KCl and 5 mM DTT.  
Two µls of 6X loading buffer (40% sucrose, 0.25% (w/v) bromophenol blue, 0.25% 
(w/v) xylene cyanol) was added and the samples were loaded onto a 6% native gel 
prepared in 0.5X Tris-borate-EDTA buffer (92). Samples were electrophoresed at 15 mA 
for approximately 1.5 hours and gels were processed as described above.    
Polyacrylamide gel electrophoresis. Six % (w/v) native polyacrylamide (29:1 
acrylamide:bisacrylamide) gels were prepared and electrophoresis was performed as 
described (92). Sixteen % (w/v) SDS-polyacrylamide gels were prepared for protein 











Primer name Sequence 5ʹ-3ʹ 
R104E sense ACAAAAAACCCAACGTGCCCACCATTGAAACAGCAAAGGTACAATAAC 
R104E antisense GTTATTGTACCTTTGCTGTTTCAATGGTGGGCACGTTGGGTTTTTTGT 
Y90A sense GTTTGCTGGACACCAGGGAGCAGCGACTGGTTTACCAAACAAAAA 
Y90A antisense TTTTTGTTTGGTAAACCAGTCGCTGCTCCCTGGTGTCCAGCAAAC 
K81A sense TGGAGTTGTCTATGTCATGTATGCGCTGTTTGCTGGACACCAGGGA 
K81A antisense TCCCTGGTGTCCAGCAAACAGCGCATACATGACATAGACAACTCC 
F83A sense GAGTTGTCTATGTCATGTATAAACTGGCGGCTGGACACCAGGGAGCA 
F83A antisense TGCTCCCTGGTGTCCAGCCGCCAGTTTATACATGACATAGACAACTC 
H86A sense CATGTATAAACTGTTTGCTGGAGCGCAGGGAGCATACACTGGTTTAC 
H86A antisense GTAAACCAGTGTATGCTCCCTGCGCTCCAGCAAACAGTTTATACATG 














Assays used to examine 3AB chaperone activity. The chaperone activity of 
3AB was evaluated using three different assays that measure annealing of complementary 
nucleic acids and aggregation. The primer-template annealing assay indirectly tests helix 
destabilization and aggregation activities by testing the ability of a chaperone to stimulate 
annealing of a primer to a larger template using gel-shift (23). Chaperone proteins 
presumably accelerate annealing in the assay through aggregation and partial unwinding 
of the large template. The aggregation assay tests the chaperone’s ability to induce 
aggregate formation, a common, though not exclusive property of chaperones. Incubation 
of chaperones with nucleic acid can result in the formation of large aggregates consisting 
of the chaperone and nucleic acid (which is generally labeled with radioactivity in the 
assay). Aggregated material can be isolated by slow speed centrifugation in a microfuge 
(4). The fluorescence resonance energy transfer (FRET) unwinding assay measures 
unwinding and annealing stimulation. The assay illustrated in Figure 2.2 was developed 
in the DeStefano lab for examining chaperones (23, 41, 69). It is rapid and produces 
immediate results that typically correlate well with the primer-template annealing assay. 
Complementary nucleic acid strands that have little structure or form stem-loops are used 
in the assay. One complement has a fluorescing group (FAM) at the 5ʹ end and the 
second has a quenching group (DABCYL) at the 3ʹ end. The thermodynamic stability of 
the strands can be varied by changing the G-C content of the stem (69). When the 
individual complements form stem-loops, they hybridize poorly at low temperature (30-
37°C is typically used). In the presence of a chaperone, partial unwinding of the stem 






Figure 2-2: Schematic representation of FRET unwinding assay and predicted 
structure of complementary substrates: Folded structure of complementary 42-
nucleotide DNA structures had ΔG values of approximately -7.2 kcal/mol as predicted 
from DNA fold (118). One complement had a FAM group (fluorophor) at the 5ʹ end, 
while the other had a DBCYL group (quencher) at the 3ʹ end. A chaperone protein like 
3AB unwinds complementary nucleic acid strands and promotes hybridization. This 









Annealing is measured by the quenching of the fluorescence signal that occurs 
when the FAM and DABCYL groups become juxtaposed upon hybrid formation. In 
assays using complements with highly stable stem regions (as in the current report), the 
major parameter tested is the ability of the chaperone to unwind the stem. Gel-shift 
assays will be used to evaluate the affinity of the mutated and wild type proteins for 
nucleic acid. 
Mutations in the 3B region of 3AB inhibit chaperone activity while 3B by 
itself shows no chaperone activity. Amino acids in the 3B region of 3AB are known to 
be pivotal for 3AB binding to nucleic acids and complex formation with 3D
pol
. Previous 
results showed that the R104E (arginine to glutamate) mutation severely disrupts binding 
to nucleic acid (110). The effect of this mutation on chaperone activity was tested using 
the FRET unwinding assay and, as expected, no significant chaperone activity was 
detected (Figure 2-3).  A second mutation, Y90A (tyrosine to alanine), was also tested. 
Tyrosine 90 is the amino acid that is uridylylated by 3D
pol
 during replication (see chapter 
1). In addition, aromatic amino acids are pivotal to the chaperone activity of HIV 
nucleocapsid protein (NC) and are presumed important in the disruption of secondary 
strucutures. The Y90A mutation also decreased chaperone activity although a low level 
of activity was detected. A double mutant with R104E and Y90A (Y90A/R104E) was 
also tested and found to be similar to R104E.   
 It was clear from the above results that the 3B region of 3AB was pivotal to 
chaperone acitivity. To test its role further the 22 amino acid 3B protein was chemically 
synthesized and tested for chaperone activity. No activity was observed, even at very 






Figure 2-3: FRET unwinding assay results: Top panel shows the FRET unwwinding 
time course assay with wildtype 3AB, 3AB-R104E, 3AB-Y90A, 3AB-R104E/Y90A, 3B 
(VPg) and HIV NC all at 2µM. Bottom panel shows FRET unwinding assay for wildtype 





showed maximal activity (Table 2-3).  Based on these results, we concluded that the 3B 
region of 3AB was necessary but not sufficienct for chaperone activity.    
The putative C-terminal cytoplasmic domain of 3AB possess chaperone 
activity at high concentrations. Since 3AB is a membrane protein, it is likely that the 
intrinsic chaperone activity resides in a portion of the protein that is cyctoplasmic 
allowing direct intereaction with nucleic acids. Models for 3AB interactions with 
membranes suggest that both the first 58 amino acid in the N-terminus and the last 29 
amino acids in the C-terminus are cytoplasmic (Figure 4-1). Since interactions with 
nucleic acids map mostly to the N-terminus, this was clearly the region most likely to 
contain intinsic chaperone activity, alhtough none was detected in 3B alone (see above). 
The last 7 amino acid of 3A are proposed to lie just outside the membrane and are 
connected to the membrane insertion domain. These 7 amino acids and the 22 of 3B 
compose the C-terminal cytoplasmic domain. Chemically synthesized 3B+7 was tested in 
the FRET unwinding assay at various concentrations.  Although very low chaperone 
activity was detected at concentrations where 3AB showed high activity (2 µM), activity 
increased at higher concentrations (8 µM) and high activity was observed with 100 µM 
3B+7 (Figure 2-3).   
Several 3B+7 proteins containing mutations were chemically synthesized and 
tested in the FRET unwinding assay (Table 2-3). Proteins containing the same mutation 
as those tested in 3AB were tested first (3B+7 R104E and Y90A, as well as R104A) to 
see if they had a similar affect on the activity of 3B+7. Similar to what was observed with 
3AB, R104E dramatically reduced the chaperone activity of 3B+7 while Y90A was 





Additional mutations residing in the connection domain including F83A (phenylalanine 
to alanine) and K81A (lysine to alanine) showed results similar to Y90A while H86A 
(histidine to alanine) showed greater chaperone activity than those mutants but slighlty 
less than wild type.  From the limited number of mutations that were tested, 3B+7 
appeared to mimic wild type 3AB’s behavior, albeit at the much higher concentration that 
was required to observe activity.   
Full length 3AB proteins containing the same mutations in the connection domain 
(F83A, K81A and H86A) as those tested in 3B+7 were tested to see if they had a similar 
affect on the chaperone activity of 3AB (Table 2-3). Similar to what was observed in 
3B+7, H86A showed greater chaperone activity than the other two mutants and was 
comparable to wildtype at a lower concentration. K81A showed results similar to Y90A, 
even in the context of the full length 3AB protein. F83A in 3AB on the other hand 
showed a slightly increased chaperone activity but still less than wildtype.  
Wild type 3AB is much more potent than 3B+7 in the primer-template 
annealing assay. Proteins were next compared in the primer-template annealing assay 
using a fixed time point protein titration. Wild type 3AB stimulated annealing strongly as 
the concentration of the protein was increased (Figure 2-4). Peak activity occurred at ~1 
µM under the conditions used, similar to what was previously observed (23). In contrast, 
the Y90A and Y90A/R104E mutants showed no annealing activity in this assay (Table 2-
3 ). Protein 3B+7 showed some annealing activity in the assay though reduced compared 
to wild type protein, even when very high concentrations were used (Figure 2-5). The 
H86A mutation in 3B+7 resulted in annealing that was detectable but lower than non-





unwinding assay for these proteins (Table 2-3). Other tested mutations in 3B+7 including 
Y90A and R104E and Y90A/R104E, showed no activity in the assay as did 3B (Table 2-







Figure 2-4: Primer template annealing assay with wildtype 3AB.  A 25 nucleotide 5' 
end-labeled RNA primer that was complementary to a 230 nucleotide RNA template was 
used in the assay. The primer and template were incubated with decreasing amounts of 
wild type 3AB (l-r: 2, 1, 0.5, 0.25, 0.013, 0.0063 or 0.0031 μM). Samples were processed 
and run on a 6% native polyacrylamide gel as described under section 2.2. The positions 
of the primer and annealed primer-template hybrid are indicated. Three controls (A–C) 









Figure 2-5: Primer-template annealing assay with wild type 3B+7. The amount of 
3B+7 protein used was: l-r, 200, 100, 50, 25, 12.5, 6.3 or 3.1 μM. See figure 2-4 and 











Wild type 3AB and 3B+7 induce aggregate formation while mutated versions 
of these proteins with low unwinding and primer-template annealing activity do not. 
Large aggregates that can form in the presence of chaperone proteins and nucleic acids 
can help to induce the formation of hybrids (4, 100). An aggregation assay was 
performed with wild type 3AB, Y90A, Y90A/R104E, 3B+7 (and various mutations), and 
3B.  Wild type 3AB induced aggregate formation in a concentration-dependent manner 
(data not shown), similar to what was observed in the primer-template annealing assay. 
Full-length proteins were tested at 2 µM and 3B or 3B+7 at 100 µM. Of those proteins 
tested wild type 3AB showed the highest level of aggregation and was essentially equal 
to HIV NC, a protein known to aggregate efficiently (Table 2-3). In addtion, 3B+7 
showed aggregation activity slighlty lower than 3AB while 3B+7-H86A showed some 
activity. All other tested proteins did not aggregate the RNA template.  
Affinity of 3AB and mutated proteins for nucleic acid. Gel-shift assays can be 
used to estimate the binding affinity of 3AB for nucleic acids. Although this method does 
not yield an accurate equilibrium binding constant, it is useful for comparing various 
3AB mutations (110). A simpler nitrocellulose filter binding assay proved unreliable in 
our hands as the amount of nucleic acid retained on the filters in the presence of 3AB was 
low and variable.  Wild type 3AB was able to gel shift nucleic acid in this assay 
consistent with previous reports  (Figure 2-6). In contrast, mutations Y90A, R104E, and 
Y90A/R104E did not shift any nucleic acid indicating that they have lower affinity for 
nucleic acid (Figure 2-6 and Table 2-3). The result is completely expected for R104E and 
Y90A/R104E as the R104E mutation was previously shown to abrogate nucleic acid 





unwinding assay it would be expected that nucleic acid binding would occur; however, it 
was not detected by gel shift, perhaps because binding was too weak (see Discussion). 
Protein 3B+7 was unable to shift nucleic acids in the gel shift assay or reliably retain 


















Figure 2-6: Gel-shift assay to test protein-nucleic acid binding. Proteins (type and 
amount as indicated) were incubated with a 40 nucleotide 5' end-labeled RNA and run on 
a 6% native polyacrylamide as described in section 2.2. The positions of the unshifted 40-











3B and 3B+7 proteins were made by chemical synthesis. All others were 
expressed and purified from E. coli. 
b
+++, ~75–100%; ++, ~25–74%; +, ~5–24%; -, 
<5%; ND, Not Determined. All relative to 3AB wild type. See Figure 2-3 for FRET 
unwinding assay. 
c
Aggregation, determined by formation of a nucleic acid pellet using 
slow speed centrifugation (Section 2-2). 
d
Primer-template annealing (see Figures. 2-4 and 
2-5). 
e
Rate constant (k) for FRET assays was determined as described in Methods. 
Results are an average of two or more experiments +/- standard deviation. 
f
In FRET 
assays, 2 μM 3B+7 showed little stimulation while 8 μM showed some stimulation (+). 
 
a








FRET rate constant 
3AB (2µM) +++ +++ +++ 0.79 ± 0.21 
3AB-Y90A (2M) + _ _ ND 
3AB-R104E (2M) _ ND _ ND 
3AB-Y90A/R104E (2M) _ _ _ ND 
3AB-K81A (2M) + + + ND 
3AB-F83A (2M) ++ ++ ++ ND 
3AB-H86A (2M) +++ +++ +++ ND 
3B (100M) _ _ _ 0.030 ± 0.001 
f
3B+7 (100M) +++ ++ ++ 0.59 ± 0.07 
3B+7-K81A (100M) + ND ND 0.13 ± 0.02 
3B+7-F83A (100M) + ND ND 0.095 ± 0.049 
3B+7-H86A (100M) ++ + + 0.21 ± 0.06 
3B+7-Y90A (100M) + _ _ 0.15 ± 0.02 
3B+7-R014A (100M) _ ND ND ND 






This report presents the most recent advances in the understanding of how 
poliovirus 3AB functions as a nucleic acid chaperone in vitro. The importance of the 3B 
region of the protein in chaperone activity has been clearly demonstrated as mutations in 
this region severely weaken or abolish chaperone activity (Table 2-3). Thus far all of the 
3B region mutations tested in the context of the full-length protein (Y90A, R104E, and 
Y90A/R104E) showed highly reduced nucleic acid binding, which explains the low 
chaperone acitivity. The 3B region of 3AB is known to be pivotal for nucleic acid 
binding so the results are not surprising (110). For single point mutations to have such a 
dramatic effect on nucleic acid binding, it is likely that they disrupt the structure of the 
3B region. Both Y90A and R104E make additional contacts with other amino acid in the 
3B (VPg) solution structure and the mutations tested would likely disrupt some or all of 
the interactions as seen in Figure 2-7 (94, 95). In fact, R104 interacts with nearly every 
amino acid residue in the C-terminal end of 3B in the proposed solution structure. Both 
R104 and Y90 lie on the same face of 3B along with several other amino acid residues 
that are conserved among picornaviruses (G88, G92, K96, K97, P101 and Q109). Future 
work would include evaluating the effect of mutations in these conserved residues on 















Figure 2-7: Structural location of amino acid tyrosine and arginine in the context of 
Vpg or 3B. Comparison of the structures calculated for PV-VPg in buffer (a) and in the 
presence of 1 M TMAO. (b) The top 10 structures in buffer alone show much more 
conformational flexibility, both in the backbone and in the position of the 
conserved side chains. (c) Inter-residue constraints (automatically assigned) used in 
determining the VPg structure in TMAO. Reprinted from Peptides, 27, Catherine H. 
Schein, Numan Oezguen,David E. Volk, Ravindranath Garimella, Aniko Paul, Werner 
Braun, NMR structure of the viral peptide linked to the genome (VPg) of poliovirus, 
1676-1684, Copyright (2006), with permission from Elsevier. This figure shows the 
structural location of mutations Y90A and R014E as Tyr 3 and Arg 17 respectively in the 








The most interesting result from this work was the finding that the putative C-
terminal cytoplasmic domain of 3AB (termed 3B+7 in this work), but not 3B by itself, 
possessed chaperone activity. In the FRET unwinding assay, which measures mostly the 
ability of a chaperone to unwind nucleic acids, 3B+7 showed activity that was 
approximately 50-fold lower than 3AB on a per mole basis. This was based on saturation 
of the rate of annealing in the FRET unwinding assay requiring ~2 µM 3AB and ~100 
µM 3B+7. Still, each protein was able to stimulate unwinding to about the same maximal 
rate. Mutations in 3B+7 behaved similar to the same mutations in the wild type protein 
for the few that were examined including R104E, Y90A, and Y90A/R104E, with the 
R104E and the double mutant showing essentially no activity in the FRET unwinding 
assay and Y90A a low level. This suggests that 3B+7 may be a reliable though 
incomplete (see below) model for examining the chaperone activity of 3AB. A R104A 
mutation in 3B+7 also showed very little activity indicating that the added minus charge 
of R104E was not responsible for the loss of activity.   
 Since 3B+7 showed chaperone activity while 3B did not, it was clear that the 7 
additional amino acids from the C-terminal end of 3A were pivotal. Three mutations were 
made in this region and tested in the context of 3B+7 and 3AB. Two of them, K81A and 
F83A, showed reduced activity similar to the Y90A mutation in 3B+7. In contrast, H86A 
showed more activity but still less than wild type 3B+7. These results were similar when 
tested in the context of full length 3AB protein as well, although there was a slight 
increase in activity of H86A and F83A when tested in full length 3AB. The results 
reiterates the importance of postively charged and aromatic amino acid in chaperone 





 It is also interesting that the 29 amino acids of 3B+7 comprise the entire putative 
C-terminal cytoplasmic domain of 3AB. This means that intrisic chaperone activity in 
vitro requires only that part of the C-terminal region of the protein that would be 
available for nucleic acid binding in vivo. The membrane anchor domain (amino acid 59-
80) would presumably be embeded in membranes in vivo and this would prevent direct 
access to nucleic acid. The N-terminal 58 amino acids of 3A are also predicted to be 
cytoplasmic and could therefore be involved with direct contacts to nucleic acids. 
However, judging from the limited affect of mutation in this region on nucleic acid 
binding (110), a direct role in chaperone activity seems less likely, although an indirect 
role that enhances activity is possible for this region and the membrane anchor domain 
(see below) 
At this point, it is difficult to speculate what roles the 3B and +7 region play in 
chaperone acitivity or how these region interact. One possible explanation is that 3B+7 
simply binds nucleic acid better than 3B. While this remains possible, we were unable to 
detect binding in gel-shift or filter binding assays with either protein and these proteins 
did not aggregate nucleic acids. Still, it is clear that 3B+7 does interact with nucleic acids 
as it would not show activity in the FRET unwinding and primer-template annealing 
assays if it did not. Possible explanations for the lack of binding in gel-shift assays are 
that that 3B+7 is too small to produce a reliable shift, the binding is too weak to survive 
this assay, or the protein simply does not work in this type of assay, as is the case for 
many other nucleic acid binding proteins. As for the filter binding assay, even full-length 
3AB did not work well in this assay, so it was not surprising that 3B+7 did not.  We are 





These assays should help in analyzing difference in binding between various mutants and 
wild type protein.  
Another possible explanation of why both 3B and the additional 7 amino acids are 
required for activity is that they form a folded complex together that has intrisic 
chaperone activity. Although possible, this explanation is weakened by the fact that 3B 
by itself forms a defined structure in solution that has been solved using NMR (93, 95). 
In addition, chemically synthesized 3B is active in uridylylation assays in which two 
UMP residues are added to tyrosine 90 by 3D
pol
 in the presence of poly(rA) or the CRE 
genome region, the natural template for uridylylation (see Introduction). These findings 
suggest 3B forms an active complex, at least for uridylylation, in the absence of the 7 
amino acid from 3A, and that chemically synthesized 3B folds correctly. 
It was interesting that the various assays used to test chaperone activity gave 
different results with particular 3AB mutations. Wild type 3AB showed high activity in 
the FRET unwinding assay while 3AB-Y90A showed low but measurable activity. The 
same senario was observed with 3B+7 and 3B+7-Y90A, albeit at higher protein 
concentrations. In contrast, only wild type 3AB gel-shifted nucleic acid and only 3AB, 
3B+7, and 3B+7-H86A aggregated RNA template. In the primer-template annealing 
assay wild type 3AB was most active and 3B+7 also showed modest activity and 3B+7-
H86A low activity. None of the other mutated proteins, even those that showed some 
activity in the FRET unwinding assay, were able to anneal primer-template. This may be 
due to the primer-template annealing assay requiring both unwinding and aggregation 
activity while the FRET unwinding assay requires mostly the former. Both wild type 





aggregation assays, respectivley. This  leads to greater annealing in the primer-template 
assay which is dependent on both activities. The only other mutated protein to show some 
activity in the primer-template annealing assay was 3B+7-H86A. This protein had low 
but measurable aggregation activity and reasonably high activity in the FRET-unwinding 
assay. This may have resulted in the low level of primer-template annealing that was 
observed. These results also point out the importance of measuring chaperone acitivity in 
more than one type of assay and using assay that focus on particular aspects of that 



















Chapter 3: Effect of mutations in the putative chaperone domain of 
3AB on replication of virus in tissue culture 
3.1 Introduction 
The molecular mechanism of viral RNA replication in poliovirus infected cells 
has been a subject of much investigation. Protein 3AB is a multifunctional protein that is 
indispensable for virus replication (Section 1-10). The first genetic evidence for the role 
of 3AB in virus replication was reported by Berstein and Baltimore (10). A cold sensitive 
mutant of poliovirus having a single amino acid insertion in the 3A region was isolated. 
This mutant formed small plaques and was defective in RNA replication at the restrictive 
temperature. Since then, several mutants defective in RNA synthesis have been isolated 
(36, 37, 101, 103, 104). Many of these were mapped to the hydrophobic domain of 3AB, 
which anchors the replication complex on membrane vesicles. In addition to affecting 
RNA synthesis, some mutations in the hydrophobic domain lead to aberrant polyprotein 
processing when viral RNAs obtained from transcription of plasmid DNA containing 
mutations are used to program HeLa cell extracts for in vitro translation. This suggests 
that 3AB may be involved in polyprotein processing as well as RNA synthesis. Mutations 
in the 3B (VPg) region of the protein lead to both lethal and non-lethal mutants with 
severe defects in RNA synthesis, as this region is important for uridylation and 3D
pol
 
binding (55).  
Work in our lab has recently established 3AB as a nucleic acid chaperone protein, 
although the importance of its chaperone activity in the virus life cycle has not been 







 traverse the highly structured genome, promoting recombination and facilitating 
structural switches that maybe important for the genome to function in translation, 
replication and packaging. Exactly how chaperones function to enhance virus replication 
in vivo remains unclear.  An ideal assay for RNA chaperone activity would be the in vivo 
demonstration of chaperone activity with its natural RNA partner, however, the 
technology for such an assay is lacking. The development and analysis of RNA 
chaperone activity in vivo/in situ is complicated by the ubiquitous nature of viral 
chaperones, all of which appear to have multiple functions at various steps of the virus 
life cycle.  These reasons are in part responsible for the lack of appropriate in vivo 
systems for the analysis of RNA chaperone activity, and for a tendency to use complex in 
vitro systems with defined components.  
In this report, we describe the effect of point mutations within the putative 
chaperone domain of 3AB (3B+7 domain described in Chapter 2) on replication of the 
virus in tissue culture. Specifically, we focused on the 7 amino acid connection domain at 
the C-terminus of 3A (+7 region of 3B+7) since mutations in this region have not been 
extensively characterized. As there are no defined in vivo assays to directly test 
chaperone function on viral RNA, these mutations are tested for their effect on plaque 
formation (viral infectivity), in vitro translation/polyprotein processing and RNA 
replication using HeLa cell extracts. These same mutations were also tested in in vitro 
chaperone assays as shown in Chapter 2. We observed that viruses containing 3AB-
K81A and 3AB-F83A produced small and minute plaques respectively compared to wild-
type 3AB. In vitro translation and polyprotein processing were not affected by these 





K81A compared to wild-type. Future work would include evaluating particular steps in 
virus replication that are affected, specifically positive/negative strand synthesis and VPg 




















3.2 Materials and Methods 
3.2.1 Materials 
All synthetic oligonucleotides (Table 2-2) were custom – ordered from Integrated 
DNA technologies Inc. (IDT). Point mutations in 3AB were made using the Quickchange 
Lightening Site-Directed Mutagenesis kit from Agilent technologies. T4 DNA ligase was 
from Invitrogen. Restriction enzymes were from New England Biolabs. Dulbecco’s 
Modified Eagle Medium (DMEM) and Fetal Bovine Serum (FBS) were from Lonza.   
3.2.2 Methods 
Random mutagenesis of the poliovirus P2-P3 region: Point mutations within 
the connection domain (3B+7) of 3AB were introduced in plasmid pXpA-P2P3 using 
Quickchange Lightening Site-Directed Mutagenesis kit according to the manufacturer’s 
protocol. Plasmid pXpA-P2P3 contains the cDNA of poliovirus RNA lacking structural 
protein coding sequences, under control of a T7 RNA polymerase promoter. All plasmids 
were analyzed by DNA sequencing using specific primers that flank the mutation. Polio-
specific RNA produced from this plasmid is capable of autonomous replication but does 
not produce infectious virus. The mutation containing fragment was then recloned into 
pXpA-SH. pXpA-SH contains full-length cDNA of poliovirus type 1 under control of the 
T7 promoter, with the hammerhead ribozyme coding sequence at the 5′end of the 
poliovirus sequence and additional unique restriction sites within the viral cDNA (9).  
RNA transcription: Full length plasmids pXpA-SH containing wild-type 3AB or 





Eco RI. Linearized plasmids were purified using phenol chloroform extractions and 
precipitated with ethanol.  Transcription reactions were performed using a MEGAscript 
in vitro transcription kit (Ambion, Inc). RNAs were purified using phenol-chloroform 
extractions and precipitated with ethanol. Following precipitation, RNAs were further 
purified using Clontech Chroma Spin-100 columns. The RNA was run on an agaorse gel 
to visualize its quality and its concentration was estimated by A260.  
RNA transfection and characterization of virus infectivity:  RNA transfections 
were performed using the TransIT-mRNA transfection kit (Mirus) according to the 
manufacturer's protocol. One microgram of RNA was used to transfect HeLa cells 
(1.5x10
6 
cells) at 80% confluency in 35-mm 6-well plates. A ten – fold serial dilution of 
RNA was carried out to compare the infectivity of the virus produced from wildtype or 
mutant transcript. Following incubation at room temperature for 1 h, the monolayers were 
overlaid with 0.5% agarose in high glucose DMEM supplemented with 0.5mM sodium 
pyruvate, 0.5X penicillin/streptomycin, 1mM L-glutamine and 10 % (0.2%) FBS. Visible 
plaques were formed following 2-3 days post transfection.    
Extraction of viral RNA and synthesis of cDNA: Viral RNA was extracted 
from plaques using the QIAamp Viral RNA Mini Kit (Qiagen) according to 
manufacturer's specifications. Full length cDNAs were prepared using Random Nona-
mer (9 mer) primer supplied with the reverse transcriptase MonsterScript 1
st
 Strand 
cDNA Synthesis Kit (EpiCenter). The fragments containing the 3AB sequence were 
amplified by PCR using specific primers (Table 2-2). These fragments were then 





Coupled in vitro translation-replication assay: In vitro translation assays were 
performed using reactions mixtures containing the following components: 51% (vol/vol) 
HeLa cell S10 cytoplasmic extract, 20% (vol/vol) HeLa ribosomal salt wash, 10% 
(vol/vol) ATP –generating mixture containing creatine phosphate, creatine kinase and all 
nucleotides except CTP, and 2mM guanidine hydrochloride. CTP is excluded out of this 
mixture as it is substituted by [α-
32
P] radiolabelled CTP to detect RNA synthesis in vitro. 
Guanidine hydrochloride is a reversible inhibitor of poliovirus replication and is used to 
completely inhibit RNA synthesis in an in vitro translation-replication reaction (8, 67). 
Reaction mixtures (50ul) were programmed with 2.5µg full length viral RNA. HeLa 
ribosomal salt wash was prepared as described by Brown and Ehrenfeld (15).  For 
analysis of translation products, 9µl aliquots (out of the 50µl reaction mixture) were 




methionine and incubated at 34°C for 3.5 h. At the end of 
3.5 h, the 10µl translation reactions were heated to 95°C for 5 mins in presence of 2X 
sample buffer. Five microliters of sample was loaded for separation of proteins by 
electrophoresis in sodium dodecyl sulfate (SDS)-12% polyacrylamide gel. The gel was 
fixed with 10% glacial acetic acid-40% methanol in water, dried and subjected to 
autoradiography on HyBlot CL film.  The remaining 40µl of the reaction mixture was 
used for analysis of RNA synthesis. PV RNA synthesis was assayed using preinitiation 
RNA complexes formed in translation-replication reactions at 34°C for 3.5 h. These 
preinitiation RNA complexes were obtained by centrifugation of the above reaction 
mixture for 20 min at 15,000 x g at 4°C. Supernatants were removed and the replication 
complexes were resuspended in replication mix containing the following components: 





generating mixture containing creatine phosphate, creatine kinase and all nucleotides 
except CTP and 400µCi of [α-
32
P] CTP. After 1h incubation at 37°C, total RNA was 
isolated using an RNeasy Mini Kit (Qiagen) and precipitated with ethanol. RNAs were 
denatured by incubation in glyoxal-dimethly sulfoxide buffer at 65°C for 45 mins and 
separated by electrophoresis on a native 1% agarose NorthernMax Glyoxal gel containing 
ethidium bromide. Equal loading of samples on the gel was confirmed by UV 
examination of 18S and 28S rRNA in each lane. The gel was dried and 
32
P-labelled RNA 
































Figure 3-1: Schematic representation of coupled in vitro translation-replication 
assay 
Master mix for translation 
HeLa cell S
10
 cytoplasmic extract 
Ribosomal salt wash 
ATP regenerating nucleotide mixture without CTP 
Guanidine Hydrochloride (Inhibitor of replication) 
RNA transcript 
50µl 
9µl master mix + 1ul 
35
S methionine Remaining master mix without 
35
S methionine 
Incubate at 34° C for 3.5h 
Spin @ 16,000rpm for 20min at 4°C to 
isolate replication complex 
Add 10ul of 2X sample buffer and incubate at 
95°C for 5 min 
Discard supernatant to get rid 
of GuHCl 





ATP regenerating nucleotide mixture without CTP 




Incubate at 37° C for 1h 
Load 5µl sample on a 12% SDS -PAGE gel 
Purify RNA using Qiagen RNeasy kit 
Overnight ethanol precipitation of RNA 
Incubate RNA with 10X glyoxal dye at 65°C for 1h 





PCR primers Sequence 5ʹ-3ʹ 
B3 TAGAGACTTGTATGCCTACG 
E4 GATGGAGTCTTGATCGTGAA 
Sequencing primers  
Pr4 ACCAGCAAACTTTAAGAGATG 
E4 GATGGAGTCTTGATCGTGAA 


















Infectivity of poliovirus RNAs with mutations in the putative chaperone 
domain of 3AB. Amino acids lysine and phenylalanine at position 81 and 83 respectively 
are highly conserved among picornavirus 3AB proteins and may be important for virus 
replication (99). Mutations K81A and F83A were introduced within 3AB  into plasmid 
pXpA-SH. pXpA-SH contains full-length cDNA of poliovirus type 1 under control of the 
T7 promoter, with the hammerhead ribozyme coding sequence at the 5′end of the 
poliovirus sequence and additional unique restriction sites within the viral cDNA (9). 
HeLa cell monolayers were transfected with serial dilutions of full length RNA 
transcripts obtained from these constructs as described in the methods section. Viral 
infectivity, defined as number of plaque forming units per microgram of RNA was 
determined for each of these mutants. Our results indicate that K81A mutation had an 
infectivity of 2.2X10
5
 which is almost similar to wildtype at 3.7X10
5
, and produced 
slightly smaller plaques (Figure 3-2) in comparison to the wildytpe.  F83A mutation had 
very low infectivity and produced minute plaques (Figure 3-2). These results are slightly 
different from what we observed in vitro. The effect of K81A mutation on chaperone 
activity in vitro was more severe than the effect of F83A mutation in the context of full 
length 3AB protein. However in tissue culture, K81A showed only a slight decrease in 
infectivity and plaque size compared to wildtype 3AB. 
On the other hand F83A showed slightly better chaperone activity than K81A in 
vitro but much lower infectivity of 15 and a more severe effect on plaque phenotype 
(Figure 3-2). It is possible that the F83A mutation could have severe effects on other 





and positive strand synthesis, which may or may not require the chaperone activity of 
3AB. The effect of K81A mutation in tissue culture suggests that a decrease in chaperone 























Figure 3-2: Plaque morphology of wildtype PV-3AB, PV-3AB-K81A and PV-3AB-
F83A mutants. HeLa cell monolayers were transfected with serial dilutions of RNA 
transcript and overlaid with high glucose DMEM containing 0.5% agaorse 1 h after 
transfection.  Plates were incubated at 37°C and stained with crystal violet 48 h after 
transfection. A) Mock transfection carried out in the absence of viral RNA. This was 
done to test the transfection reagents for contamination. B) Transfection with wildtype 
PV-3AB. C) Transfection with PV-3AB-K81A. D) Transfection with PV-3AB-F83A. 











 and no RNA 
control. Infectivity for wildtype is 3.7X10
5
, K81A is 2.2X10
5 
and F83A is 15 plaque 
forming units per microgram of RNA used.  Each of the transfection plate has a well that 








Comparison of cDNA sequences derived from plaque purified viral RNA 
containing mutations within the putative chaperone domain of 3AB. 3AB sequence 
of poliovirus cDNA obtained from plaques generated by transfection with K81A RNA 
transcripts was determined. 3AB sequence of poliovirus cDNA obtained from revertants 
as a result of transfection with F83A RNA transcript was also determined. All primers for 
PCR and sequences are listed in Table 3-1. Comparison of five cDNA sequences from 
plaques derived from K81A mutation containing transcript showed that the virus 
maintained the original K81A mutation (AAA to GCG) indicating that this change does 
not apply any selective pressure on the virus to survive and hence gave rise to no 
compensatory mutations within the 3AB region of the genome.  
Transfection with F83A RNA did not form clear plaques. Upon incubating the 
plates for a longer duration (4 days), some revertants developed. Comparison of nine 
cDNA sequences from these revertants showed that the virus reverts back to the wildtype 
in most cases, indicating that this mutation was not well tolerated by the virus. In one 
case, the virus retains the original F83A mutation (TTT to GCG) (Figure 3-3) and in 
another case, there is a mixed population of the virus containing the original mutation or 
converting to ACG (Figure 3-3, 3-4) which codes for threonine. These results do not 
eliminate the existence of other mutations in the rest of the viral genome that may 
contribute to the observed plaque phenotype, infectivity and difference in RNA synthesis 









Figure 3-3: Comparison of cDNA sequences derived from plaque purified viral 
RNA containing mutations within the putative chaperone domain of 3AB. 
Top panel A: The yellow highlighted region between nucleotides 5351-5353 indicates the 
K81A mutation compared to wildtype (topmost sequence). All five plaques sequenced 
retain the K81A mutation.  
Bottom panel B: The yellow highlighted region between nucleotides 5358-5360 indicates 
the F83A mutation compared to wildtype (topmost sequence). Seven of the nine plaques 
sequenced reverted to wildtype. The other two substituted an alanine and a threonine at 



















Figure 3-4: DNA sequence analysis of specific revertants from F83A mutations.  
Top panel: Position 383-385 clearly indicates ACG, which codes for threonine 
Bottom panel: Position 387-389 indicates a mixed population of viruses mostly 







Effect of mutations in the putative chaperone domain of 3AB on various 
steps in viral replication. To test the effect of amino acid substitution at positions 81 and 
83 on various steps in virus replication, we performed an in vitro translation-replication 
assay in HeLa cell extracts. The HeLa cell extract contains the necessary components 
required for PV RNA replication and is assumed to mimic the steps that occur in infected 
cells. In this assay, RNA transcripts from wild type pXpA-SH-3AB, pXpA-SH-K81A 
and pXpA-SH-F83A were used to program HeLa S10 extracts supplemented with 
ribosomal salt wash in the presence of [
35
S] methionine, which allows the analysis of 
protein translation and polyprotein processing independent from other viral processes 
(Figure 3-1). This part of the assay was performed in the presence of guanidine 
hydrochloride in the reaction mixture, a known inhibitor of poliovirus RNA replication. 
Analysis of labeled viral protein by SDS-PAGE showed that there was no difference in 
the pattern or levels of synthesized proteins between wildtype and mutant 3AB constructs 
(Figure 3-5), indicating that these mutations do not have any effect on protein synthesis 
and processing of precursor proteins.  
To determine whether these mutations alter the RNA production, we examined 
the ability of the HeLa cell extracts containing the proteins translated from wildtype or 
mutants RNA transcripts to synthesize RNA in vitro. Replication complexes were 
isolated by centrifugation after the translation reaction. This step is required to get rid of 
guanidine hydrochloride, an inhibitor of poliovirus replication (Figure 3-1). Analysis of 
32
P labeled RNA by agaorse gel electrophoresis showed a difference in the levels of RNA 
synthesized by wildtype and mutant transcripts. K81A showed slightly lower levels of 





compared to wildtype. These results indicate that the K81A and F83A mutations affect 
RNA synthesis. However, this system does not allow us to distinguish which steps in 
RNA replication are affected. Further work needs to be done to determine the effect of 
these mutations on different stages of viral RNA replication such as VPg uridylyation and 































Figure 3-5: In vitro translation-replication assay; protein synthesis and polyprotein 
processing. Wildtype and mutant RNA transcripts were used to program translation in 
HeLa S10 extracts supplemented with ribosomal salt wash in the presence of 
35
S 
methionine. Lane 1-4 (l-r): No RNA, F83A, K81A and wildtype 3AB. Reaction products 
were subjected to electrophoresis on a 12% polyacrylamide-SDS gel. Results indicate no 




























Figure 3-6: In vitro translation-replication assay; RNA synthesis. Replication 
complexes were isolated by centrifugation following translation in the in vitro 
translation- replication reaction. The 
32
P labeled RNA was analyzed by agaorse gel 
electrophoresis. Lanes 1-3 (l-r): Wildtype 3AB, K81A and F83A. The results indicate a 
difference in RNA levels between the mutants and the wildtype. K81A is slightly lower 














This report presents the effect of mutations within the putative chaperone domain 
(3B+7) of 3AB on replication of the virus in tissue culture. Here we have analyzed 
mutations that are associated with reduction in chaperone activity of 3AB in vitro 
(discussed in chapter 2). The two mutations tested, K81A and F83A, reside in the 
connection domain that consists of 7 amino acids at the C-terminus of the 3A (+7 region 
of 3B+7). Mutations in this region have not been extensively characterized.  
From our tissue culture assays, we found that K81A did not dramatically affect 
the infectivity and plaque phenotype of the virus in comparison to the wildtype. Sequence 
analysis of virus produced as a result of this mutation showed that the virus retained the 
original mutation (AAA to GCG) at position 81, indicating that this mutation is well 
tolerated. The in vitro translation-replication assay shows wildtype levels of protein 
synthesis and polyprotein processing ability. This is possible as chaperone activity is 
based on nucleic acid binding of the protein and polyprotein synthesis and processing 
does not require the nucleic acid interaction of 3AB. The reduced RNA levels indicate 
that K81A does have an effect on RNA replication but the exact step at which replication 
is affected has to be further analyzed (VPg uridylation and/or initiation of negative and 
positive strand synthesis). 
F83A on the other hand drastically affected viral infectivity and did not form clear 
plaques. Sequence analysis of revertants that appeared showed that the virus switches 
back to the wildtype in most cases. In vitro protein synthesis and polyprotein processing 





multifunctional protein and interacts with many proteins that are involved in replication 
(Section 1-10). The F83A mutation maybe critical for 3AB binding to other proteins that 
are involved in virus replication.  
It is quite possible that in both cases, the stage at which viral replication is 
affected may or may not require the chaperone activity of 3AB. K81A is a change from 
positive amino acid to a neutral amino acid. This change would possibly reduce RNA 
binding purely based on charge interaction and that may be the reason why a decrease in 
chaperone activity of 3AB was observed in vitro. Phenylalanine is a bulky amino acid 
and maybe involved in base stacking of nucleic acid molecules. This change could have 
an effect on RNA binding ability of 3AB and hence could be the reason for a decrease in 
chaperone activity of 3AB in vitro. These effects may have caused a decrease in RNA 
synthesis levels by affecting one or more steps in virus replication like VPg uridylation 
and/or initiation of negative and positive strand synthesis.  
3AB may be involved in recombination which occurs in high frequency in polio 
and other plus sense RNA viruses (1, 6, 28, 29). Recombination presumably occurs by a 
copy-choice mechanism that involves transfer (often referred to as “strand transfer” or 
“template-switching”) of an RNA being synthesized on one viral genome (generally 
during synthesis of the minus strand in polio) to another where synthesis continues. 
Chaperone proteins like HIV-NC can stimulate copy-choice recombination in 
reconstituted in vitro systems through accelerating the binding of complementary nucleic 
acids. Since the mutations tested above show reduced chaperone activity in vitro, they 
could decrease recombination in the virus. It will be interesting to identify mutations that 





used to develop an effective vaccine that eliminates the problem of recombination in 
current vaccine strains (see general discussion). Based on our data from this report, K81A 
is a likely candidate to be tested for recombination as it produces viable virus, normal 
level of proteins and only slightly reduced RNA levels in vitro. F83A may not be a 
suitable candidate as this mutation is not tolerated well by the virus and reverts back to 
wiltype. Viruses produced from the K81A mutation should be further tested for growth 
kinetics. If this virus does not recombine effectively but has high growth kinetics, it could 
be incorporated into current vaccine strains and tested for recombination and growth of 
















Chapter 4: General Discussion  
Proteins with RNA chaperone activity are ubiquitous in nature and play an 
important role in various cellular processes. They are important partners of RNA as they 
help maintain its correct structure by rearrangement of misfolded structures in an ATP-
independent manner at almost every stage of RNA metabolism including transcription, 
transport, storage and translation (20, 44, 81). The range of RNA chaperone proteins that 
exists varies from virus-encoded RNA chaperones, E. coli transcriptional regulator 
(StpA), many ribosomal proteins, cold-shock proteins, and E. Coli translation initiation 
factor 1 (IF1) among others (96). The field of virus-encoded chaperone proteins is 
growing rapidly and is of special interest to us (119). Our lab was the first to demonstrate 
chaperone activity of a picronavirus protein, poliovirus 3AB (23). It is important to note 
that chaperone activity is measured in the test tube so it is not always clear what role, if 
any, the observed activity is playing in the cell. For ribosomal proteins the observed 
activity is consistent with the putative function of the proteins in ribosome assembly, 
however, for viral chaperones like 3AB and HIV NC, the role is less defined.  
The aim of this dissertation was to identify the regions intrinsic to the nucleic acid 
chaperone activity of 3AB.  Previous work from our lab has shown that bacterially 
expressed purified protein 3AB possessed helix destabilizing activity and was able to 
promote hybridization of complimentary nucleic acid strands in the absence of 
nucleotides (as an energy source) (23). In Chapter 2, we were able to demonstrate that the 
3B region of 3AB is pivotal to chaperone activity but 3B by itself does not possess 





surprising. Single point mutations, R104E and Y90A, within the 3B region of the 3AB 
protein showed severely reduced chaperone activity. These residues make additional 
contact with other amino acids in the 3B solution structure and it is possible that the 
mutations disrupt some or all of these interactions (94, 95). In fact these residues lie on 
the same face of 3B as other amino acids that are conserved among picronaviruses. This 
face is critical to nucleic acid binding as well as 3AB-3D
pol
 protein-protein interactons 
(99). The mutations may directly disrupt nucleic acid binding, especially R104E which 
changes a basic amino acid to an acidic residue. They may also disrupt the structure in 
this region leading to abrogation of chaperone activity. Analysis of these mutation using 
circular dichroism (CD) or NMR may help reveal structural changes.   
The most interesting result from this work is the finding that the putative C–
terminal cytoplasmic domain of 3AB, 3B+7 possess chaperone activity at high 
concentrations. Since 3B+7 showed chaperone activity while 3B alone did not, it is clear 
that the additional seven amino acids from the C–terminal end of 3A are pivotal for the 
chaperone activity of 3AB. Three single point mutations were made in this region and 
were tested in the context of 3B+7 and full length 3AB protein. Two of them, K81A and 
F83A, showed reduced chaperone activity similar to the Y90A mutation in 3B+7.  In 
contrast H86A showed more activity but still less than wildtype 3B+7. These results 
reiterate the importance of positively charged and aromatic amino acids in chaperone 
activity. In the context of the full length 3AB protein, these mutations had similar effects 
on chaperone activity. The dramatic change from essentially no activity for 3B to 
significant activity for 3B+7 could result from the addition of aromatic and basic amino 





proteins.  It is also possible that the +7 region is needed to stabilize the structure of 3B or 
this entire region of the protein. Although an NMR structure for 3B has been solved, 
stabilizing reagents were required to obtain a structure and the protein was unstructured 
without these agents. It would be interesting to see if 3B+7 has a stable structure, even in 
the absence of stabilizing agents.    
The current results and previous results from others have allowed us to formulate 
a working model to explain the in vitro chaperone activity of 3AB (Figure 4-1).  We 
hypothesize that the intrinsic chaperone activity of 3AB resides in the 3B+7 region based 
on the chaperone activity of this protein at high concentrations (Table 2-3).  The 
membrane anchor domain of the 3A region (amino acid 59-80) serves to “concentrate” 
the 3B+7 region by stacking on itself.  This leads to an increase in the effective 
concentration of the 3B+7 region such that a lower concentration of the full-length 
protein, in comparison to 3B+7 alone, is required to obtain high chaperone activity.  In 
Figure 4-1, the membrane anchor domain is shown as the major stacking agent, although 
the N-terminal cytoplasmic domain (amino acids 1-58, labeled 3A in figure) could also 
be involved. This region has been shown by NMR to dimerize when expressed in the 
absence of the rest of the protein so interactions leading to multimer formation are 
plausible.(98)  In addition to being consistent with the current results, the proposed model 
is also consistent with 3AB’s ability to form homomultimeric complexes.(78, 109)  Note 
that no membranes are required for the proposed stacking as the assays were conducted in 
the absence of phospholipids.  Still, cellular membranes may help catalyze stacking and 
this will be examined in the future using membranes in in vitro reactions.  We are 





terminal region of 3AB.  Truncations and deletions will also be tested permitting that 































Figure 4-1: Model for in vitro 3AB chaperone activity. The intrinsic chaperone 
activity of 3AB resides in the 3B+7 region based on the chaperone activity of this protein 
at high concentrations (Table 2-3). The membrane anchor domain of the 3A region 
(amino acid 59–80) serves to “concentrate” the 3B+7 region by stacking on itself. This 
leads to an increase in the effective concentration of the 3B+7 region such that a lower 
concentration of the full-length protein, in comparison to 3B+7 alone, is required to 











We have successfully identified several mutations in 3AB (R104E, Y90A, 
R104E/Y90A, K81A, F83A) that negatively affect chaperone activity.  Previous reports 
by other groups have shown that R104E and Y90A mutations are lethal in tissue culture 
infections. We tested a few of the remaining mutations (K81A and F83A) for their effect 
on replication of the virus in tissue culture. Based on our observation (Chapter 3), a 
decrease in chaperone activity does reduce RNA synthesis in vitro. However, since 3AB 
serves many functions in viral replication, it is not clear if RNA synthesis reduction 
resulted only from a decrease in chaperone activity. No clear role for F83 or K81 has 
been deciphered in the literature. It will be necessary to examine specific steps in 
replication to try to correlate chaperone activity with a specific viral function. For a 
protein with such ubiquitous function, this may be difficult. This work is ongoing and we 
plan to determine the individual steps in virus replication that are affected (VPg 
uridylation, negative and positive strand RNA synthesis) as well as assay the level of 
recombination in the virus. It has been proposed that chaperones promote recombination 
in viruses and there is some evidence that mutations in HIV NC protein can reduce 
recombination. Alteration in recombination could be a good readout for chaperone 
function as it may be possible to produce mutants that minimally effect replication while 
dramatically reducing recombination. This could be important as one problem with the 
current virus strains used in the oral polio vaccine is the possibility of reversion via 
mutation or recombination to a more neurovirulent form while they replicate in the gut. 
There is a need for developing a modified live attenuated vaccine but with lower 
recombination or mutation frequencies. Specific mutations in poliovirus 3Dpol have been 





been added to the vaccine strain (5, 22, 33, 105, 106). The chaperone activity of 3AB can 
be used towards developing new effective vaccines that could lead to eradication 
poliovirus. Since recombination is not strictly “required” for replication, mutations that 
inhibit recombination may not necessarily inhibit replication. Therefore, we would be 
presented with a unique opportunity to identify mutations that could decrease 
recombination without affecting replication. Even if the mutations had a modest 
deleterious influence on replication kinetics, they could still find a potentially powerful 
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